The global cell therapy manufacturing market size is expected to increase USD 16.89 billion by 2033 from USD 4.20 billion in 2023 with a CAGR of 14.93% between 2024 and 2033.
Key Points
- The North America cell therapy manufacturing market size accounted for USD 1.85 billion in 2023 and is expected to attain around USD 7.43 billion by 2033.
- North America led the market with the major revenue share of 44% in 2023.
- Asia Pacific is expected to witness the fastest growth during the forecast period.
- By therapy type, the autologous cell therapy segment has held the biggest revenue share of 59% in 2023.
- By therapy type, the allogenic cell therapy segment is projected to be the fastest-growing segment over the forecast period.
- By technology type, the somatic cell technology segment held the largest share of the market in 2023.
- By technology type, the 3D technology segment is expected to grow at the fastest rate during the projected period.
- By source, the IPSC (induced pluripotent stem cell) segment dominated the market in 2023.
- By source, the bone marrow segment is the second largest segment in the global market.
- By application, the oncology segment has contributed the largest revenue share of 35% in 2023.
- By application, the neurological segment is projected to show fastest growth during the forecast period.
The cell therapy manufacturing market encompasses the processes and technologies involved in producing therapeutic cells for medical use. This rapidly evolving field focuses on developing and manufacturing cell-based therapies to treat a range of diseases, including cancer, autoimmune disorders, and genetic conditions. Cell therapy offers promising opportunities for personalized medicine by harnessing the body’s own cells to repair, regenerate, or replace damaged tissue.
Get a Sample: https://www.precedenceresearch.com/sample/4283
Growth Factors:
Several key factors are driving the growth of the cell therapy manufacturing market. One significant factor is the increasing prevalence of chronic diseases, such as cancer and cardiovascular disorders, which require innovative treatment approaches like cell therapy. Advances in biotechnology and genetic engineering have also accelerated the development of novel cell therapies. Additionally, rising investments from pharmaceutical companies and government organizations to support research and development in this field contribute to market expansion.
Region Insights:
The cell therapy manufacturing market exhibits regional variations influenced by factors such as regulatory environments, research infrastructure, and healthcare expenditure. North America and Europe are prominent regions due to established biotechnology sectors and supportive regulatory frameworks. Asia-Pacific is emerging as a significant market, driven by increasing investments in healthcare infrastructure and a growing focus on biopharmaceutical innovation in countries like China and South Korea.
Cell Therapy Manufacturing Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 14.93% |
| Cell Therapy Manufacturing Market Size in 2023 | USD 4.20 Billion |
| Cell Therapy Manufacturing Market Size in 2024 | USD 4.83 Billion |
| Cell Therapy Manufacturing Market Size by 2033 | USD 16.89 Billion |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Therapy Type, By Technology Type, By Source, and By Application |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Cell Therapy Manufacturing Market Dynamics
Drivers:
Key drivers shaping the cell therapy manufacturing market include advancements in cell culture techniques, automation of manufacturing processes, and the development of scalable production platforms. Innovative technologies like gene editing and induced pluripotent stem cells (iPSCs) are driving the expansion of therapeutic options. Moreover, collaborative efforts among research institutions, biotech firms, and academia are fostering a conducive environment for accelerated product development and commercialization.
Opportunities:
The cell therapy manufacturing market presents compelling opportunities for industry players to diversify and expand their portfolios. Opportunities lie in optimizing manufacturing processes to reduce costs, improving scalability and reproducibility of cell therapies, and enhancing product quality and safety profiles. Expansion into emerging markets and the customization of therapies for specific patient populations also offer avenues for growth and differentiation.
Challenges:
Despite its promising outlook, the cell therapy manufacturing sector faces several challenges. These include complex manufacturing processes requiring stringent quality control, scalability issues, and high costs associated with research, development, and manufacturing. Regulatory hurdles related to safety, efficacy, and manufacturing standards pose additional challenges. Addressing these challenges requires ongoing innovation, collaboration across stakeholders, and strategic investments in infrastructure and talent.
Read Also: Brazil Industrial Absorbent Market Size, Share Report by 2033
Cell Therapy Manufacturing Market Recent Developments
- In March 2024, Cellars announced the completion of the first Cell Shuttle, an automated, cGMP-compliant cell therapy manufacturing platform to support the global demand for cell therapies while reducing the cost of manufacturing and process failure rates.
- In March 2023, Cell One Partners and the Center for Breakthrough Medicines (CBM) entered into a strategic collaboration aimed at accelerating the development and commercialization of cell and gene therapies. This collaboration brings together the expertise and resources of both organizations to drive innovation and advance the field of regenerative medicine.
- In September 2022, the Cell Therapy Manufacturing Center (CTMC) and Ori Bio collaborated to expedite the process development, commercialization, and clinical integration of cell therapies. This partnership aimed to enhance the advancement of cell-based treatments and bring them to patients more efficiently.
Cell Therapy Manufacturing Market Companies
- Merck KGaA
- Thermo Fisher Scientific
- Catalent, Inc
- Bio-Techne
- Cytiva
- Lonza
- The Discovery Labs
- Novartis AG
- Bristol-Myers Squibb Company
- Gilead Sciences, Inc.
Segments Covered in the Report
By Therapy Type
- Allogenic Cell Therapy
- Autologous Cell Therapy
By Technology Type
- Somatic Cell Technology
- Cell Immortalization Technology
- Viral Vector Technology
- Genome Editing Technology
- Cell Plasticity Technology
- 3D Technology
By Source
- IPSC (Induced Pluripotent Stem Cell)
- Bone Marrow
- Umbilical Cord
- Adipose Tissues
- Neural Stem
By Application
- Musculoskeletal
- Cardiovascular
- Gastrointestinal
- Neurological
- Oncology
- Dermatology
- Others
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
